A randomised phase II study: Treatment with daily p.o. Iressa (TM) (ZD1839) or placebo in combination with weekly IV infusion of docetaxel in patients with metastatic breast cancer

Trial Profile

A randomised phase II study: Treatment with daily p.o. Iressa (TM) (ZD1839) or placebo in combination with weekly IV infusion of docetaxel in patients with metastatic breast cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2007

At a glance

  • Drugs Docetaxel; Gefitinib
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Feb 2007 Status change
    • 24 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top